Merck Reports Strong Phase 3 Results for Oral PCSK9 Inhibitor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy MRK?
Source: Yahoo Finance
- Clinical Trial Success: On March 30, 2026, Merck announced positive results from the CORALreef AddOn trial, demonstrating that the oral PCSK9 inhibitor enlicitide reduced LDL-C levels by 64.6% when combined with statins, indicating its potential in cardiovascular disease treatment.
- High Patient Success Rate: The trial showed that 78.2% of patients achieved the LDL-C target of less than 55 mg/dL, highlighting enlicitide's effectiveness and good patient adherence, which may lay the groundwork for future market promotion.
- Strategic Acquisition: On March 25, 2026, Merck acquired clinical-stage oncology company Terns Pharmaceuticals for $6.7 billion, aiming to expand its hematology portfolio and strengthen its position in oncology, reflecting its commitment to diversification strategies.
- Stable Safety Profile: Enlicitide's safety profile remained consistent with previous trials, with no serious adverse events reported, providing confidence for its future market launch and potentially attracting more investor interest in its market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Approves Merck's Idvynso for HIV Treatment
- New Drug Approval: The US FDA has approved Merck's Idvynso, a single-pill regimen combining Pifeltro (doravirine) and islatravir, marking a significant advancement in HIV treatment options.
- Innovative Mechanism: Doravirine acts as a non-nucleoside reverse transcriptase inhibitor, while islatravir is a novel nucleoside reverse transcriptase translocation inhibitor that halts HIV-1 replication by inhibiting reverse transcriptase translocation and inducing structural changes in viral DNA, showcasing its unique therapeutic mechanism.
- Clinical Trial Support: The approval is based on the results of two randomized, non-inferior trials demonstrating that Idvynso is comparable in efficacy to Gilead's Biktarvy, enhancing its competitive position in the market.
- Market Potential: With the ongoing demand for HIV treatments, the launch of Idvynso not only provides patients with a new therapeutic option but also has the potential to generate significant revenue growth for Merck in a highly competitive pharmaceutical landscape.
See More
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
See More
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
See More
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Approves Merck's Idvynso for HIV Treatment
- New Drug Approval: The US FDA has approved Merck's Idvynso, a single-pill regimen combining Pifeltro (doravirine) and islatravir, marking a significant advancement in HIV treatment options.
- Innovative Mechanism: Doravirine acts as a non-nucleoside reverse transcriptase inhibitor, while islatravir is a novel nucleoside reverse transcriptase translocation inhibitor that halts HIV-1 replication by inhibiting reverse transcriptase translocation and inducing structural changes in viral DNA, showcasing its unique therapeutic mechanism.
- Clinical Trial Support: The approval is based on the results of two randomized, non-inferior trials demonstrating that Idvynso is comparable in efficacy to Gilead's Biktarvy, enhancing its competitive position in the market.
- Market Potential: With the ongoing demand for HIV treatments, the launch of Idvynso not only provides patients with a new therapeutic option but also has the potential to generate significant revenue growth for Merck in a highly competitive pharmaceutical landscape.
See More
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
See More
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
See More
